DCM
ELVN icon

Driehaus Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Driehaus Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-64,294
Closed -$4.12M – 412
2020
Q1 		$4.12M Buy
+64,294
New +$4.1M 0.14% 163

Other funds holding ELVN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Driehaus Capital Management's ELVN Position: Q2 2020 in Review

Driehaus Capital Management sold out of Enliven Therapeutics (ELVN) in Q2 2020, closing a stake of 64,294 shares — an estimated $4.12M sold.

Driehaus Capital Management first reported a position in ELVN in Q1 2020 and held it in 1 quarter. The position peaked at $4.12M in Q1 2020. 34 funds tracked by Wall St. Rank hold ELVN as of Q2 2020.

  • Driehaus Capital Management reported no remaining Enliven Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Driehaus Capital Management sold 64,294 Enliven Therapeutics shares in Q2 2020, an estimated $4.12M.
  • Driehaus Capital Management first reported a position in Enliven Therapeutics in Q1 2020 and held it in 1 quarter.
  • Driehaus Capital Management's Enliven Therapeutics position peaked at $4.12M in Q1 2020.
  • 34 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2020.

Based on Driehaus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.